Search

Displaying results 351 - 360 of 2453 in total
  1. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by ...

  2. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at low pH

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  3. Drug

    Sodium ferric gluconate complex

    go.drugbank.com/drugs/DB09517
    Approved

    The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 – 440,000 daltons on gel chromatography.

  4. Drug

    Indocyanine green acid form

    go.drugbank.com/drugs/DB09374
    ApprovedInvestigational

    Indocyanine Green for Injection USP has a pH of approximately 6.5 when reconstituted.

  5. Drug

    PF-06282999

    go.drugbank.com/drugs/DB11683
    Investigational

    Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).

  6. Drug

    PF-06260414

    go.drugbank.com/drugs/DB15221
    Investigational

    PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

  7. Drug

    Rabeprazole

    go.drugbank.com/drugs/DB01129
    ApprovedInvestigational

    Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  8. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medica...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  9. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom ...

    Categories: P-glycoprotein substrates
  10. Drug

    PF-232798

    go.drugbank.com/drugs/DB14813
    Investigational

    PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).

    Synonyms: PF-00232798